viewRed Hat

Red Hat, AnaptysBio, Aimmune Therapeutics and more - AFTER HOURS

A look at the after hours trade in New York on Tuesday

A look at some highlights in after hours trade in New York

After stocks posted a higher finish on Wall Street, shares in Red Hat Inc (NYSE:RHT) added over 5% after the bell to US$161 on Monday.

The software group reported fourth quarter earnings per share (EPS) and revenue, which beat Wall Street expectations. Sales rose 23% year-on -year of US$772mln.

Meanwhile, AnaptysBio Inc (NASDAQ:ANAB) rose 8.79% in extended hours to US$123.83 after the drug developer announced positive peanut allergy treatment data yesterday.


Analysis of the mid-stage trial data pointed to nearly half of patients treated showing peanut tolerance.

Concurrently, fellow drug maker Aimmune Therapeutics Inc (NASDAQ:AIMT) shares dropped. Aimmune's drug to treat peanut allergy in children succeeded in a late-stage study in February.

Meanwhile, SM Energy Co (NYSE:SM) nudged 0.27% to US$18.62 after the bell after the natural gas explorer said it had completed its previously announced sale of the majority of its assets in the Powder River Basin for US$500mln.

The company plans to use the proceeds for general corporate purposes, including to reduce debt.

Quick facts: Red Hat

Price: - -

Market: NYSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

2 days, 2 hours ago

2 min read